CBL-514
Adipocyte-targeting compound (reported)
Small-molecule candidate from Caliway Biopharmaceuticals, which the developer says induces adipocyte apoptosis and lipolysis.
Evidence level. Published human clinical data exists, from trials or approved use. About the badges
- Class
- Adipocyte-targeting compound (reported)
- Category
- Fat Metabolism & Lipotropics
- Type
- Single compound
- Development and regulatory status
- Investigational, phase 2b completed; not approved
What researchers study
CBL-514 is a small-molecule candidate developed by Caliway Biopharmaceuticals. The developer says it induces adipocyte apoptosis and lipolysis, citing preclinical findings of increased caspase 3 and a higher Bax/Bcl-2 ratio.
Research areas
- Adipocyte apoptosis and lipolysis mechanisms
- Localised fat-volume measurement by MRI
- Fat-cell biology in cellular and animal models
Reported findings
Summaries of published results. Each one is tagged with the type of study behind it. They describe research outcomes and are not claims about any product. Why study type matters.
- phase 2 trial
Company-reported phase 2b (173 adults): 54.2% of CBL-514 participants had at least 20% abdominal fat-volume reduction on MRI versus 0% with placebo
- phase 2 trial
Mean fat-volume change was -22.4% with CBL-514 versus +1.8% with placebo, and adverse events were mostly mild to moderate local reactions
- phase 2 trial
In an earlier company-reported phase 2 study (76 participants), 69.6% lost at least 150 mL of fat at 8 weeks versus 0% with placebo
